Dose recommendations for anticancer drugs in patients with renal or hepatic impairment
SD Krens, G Lassche, FGA Jansman… - The Lancet …, 2019 - thelancet.com
Renal or hepatic impairment is a common comorbidity for patients with cancer either
because of the disease itself, toxicity of previous anticancer treatments, or because of other …
because of the disease itself, toxicity of previous anticancer treatments, or because of other …
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment
SD Krens, G Lassche, FGA Jansman, IME Desar… - Lancet …, 2019 - research.rug.nl
Renal or hepatic impairment is a common comorbidity for patients with cancer either
because of the disease itself, toxicity of previous anticancer treatments, or because of other …
because of the disease itself, toxicity of previous anticancer treatments, or because of other …
[引用][C] Dose recommendations for anticancer drugs in patients with renal or hepatic impairment
SD Krens, G Lassche, FGA Jansman, IME Desar… - 2019 - repository.ubn.ru.nl
Renal or hepatic impairment is a common comorbidity for patients with cancer either
because of the disease itself, toxicity of previous anticancer treatments, or because of other …
because of the disease itself, toxicity of previous anticancer treatments, or because of other …
[引用][C] Dose recommendations for anticancer drugs in patients with renal or hepatic impairment
SD Krens, G Lassche, FGA Jansman, IME Desar… - The Lancet …, 2019 - cir.nii.ac.jp
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment
SD Krens, G Lassche, FGA Jansman, IME Desar… - The Lancet …, 2019 - Elsevier
Renal or hepatic impairment is a common comorbidity for patients with cancer either
because of the disease itself, toxicity of previous anticancer treatments, or because of other …
because of the disease itself, toxicity of previous anticancer treatments, or because of other …
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment
SD Krens, G Lassche, FGA Jansman… - The Lancet …, 2019 - pubmed.ncbi.nlm.nih.gov
Renal or hepatic impairment is a common comorbidity for patients with cancer either
because of the disease itself, toxicity of previous anticancer treatments, or because of other …
because of the disease itself, toxicity of previous anticancer treatments, or because of other …
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment.
SD Krens, G Lassche, FGA Jansman… - The Lancet …, 2019 - europepmc.org
A comment on this article appears in" Use of the Child-Pugh score in anticancer drug dosing
decision making: proceed with caution." Lancet Oncol. 2019 Jun; 20 (6): e289. A comment …
decision making: proceed with caution." Lancet Oncol. 2019 Jun; 20 (6): e289. A comment …